SecBot SecBot

LXRX drug pipeline

$1.75
−2.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
1
0 with results posted

Upcoming catalysts

1 dated
  1. Jan 2027
    ZYNQUISTA
    Phase 3 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseFiled/Pre-NDA resubmission (already approved as Inpefa for heart failure)
Time to marketUncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.

ZYNQUISTA sotagliflozin Updated Sep 1

What to watch

Watch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.

Bull case
  • First-in-class dual SGLT1/SGLT2 inhibitor with a unique mechanism that could offer advantages over selective SGLT2 inhibitors for type 1 diabetes with CKD
  • Same molecule (sotagliflozin) is already FDA-approved as Inpefa for heart failure, demonstrating safety and regulatory familiarity
  • Analyst consensus is bullish: 8 analysts with 3 Strong Buy and 5 Buy ratings; mean price target of $3.86 implies ~41.6% upside from ~$2.19
Bear case
  • FDA has rejected sotagliflozin for type 1 diabetes twice, once in 2019 and again with a CRL in December 2024, and an FDA advisory committee voted 11-3 against it, indicating significant regulatory hurdles
  • An FDA advisory committee voted 11-3 against Zynquista in 2024, suggesting serious safety/efficacy concerns remain even after additional data submission
  • Elevated short volume ratio (many days >60% short volume) indicates bearish positioning from shorter-term traders
● neutral
Impact
PhasePhase 1
Time to marketUnknown — LX9851 is in Phase 1; if successful, approval would likely be 5-7+ years away, though as a partnered program with Novo Nordisk the timeline is at Novo Nordisk's discretion.

LX9851 Updated Sep 1

What to watch

LX9851 is a partnered early-stage asset, the stock will primarily trade on Lexicon's nearer-term catalysts (ZYNQUISTA NDA resubmission in Q4 2026 and SONATA-HCM Phase 3 topline in Q1 2027). The next LX9851-specific catalyst is Phase 1 completion expected Q1 2027, which could trigger additional milestone payments from Novo Nordisk. Monitor for any Phase 1 data disclosures or further milestone achievements.

Bull case
  • Novo Nordisk, the world's leading obesity drug developer, is developing LX9851, validating the mechanism and providing development expertise and funding.
  • Lexicon has already earned $20M in milestone payments (March and August 2026) and remains eligible for up to $1 billion in total milestones plus tiered royalties on future sales.
  • LX9851 is a first-in-class oral non-incretin candidate, a different mechanism than GLP-1s, with preclinical data showing enhanced weight loss when combined with semaglutide, suggesting potential as a combination therapy.
Bear case
  • LX9851 is still in Phase 1, early-stage obesity drugs have a high attrition rate and most fail to reach the market.
  • The obesity market is intensely competitive, dominated by GLP-1-based therapies (Novo Nordisk's own Wegovy/Ozempic, Eli Lilly's Mounjaro/Zepbound). A novel non-incretin mechanism faces an uphill commercial battle even if approved.
  • LX9851 is partnered with Novo Nordisk, so Lexicon has no control over development pace or strategy. Lexicon's economics are limited to milestones and royalties, not full ownership.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ZYNQUISTAA Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyPhase 3Active not recruiting500Jan 2027